In 2020 the Drug Hunter site highlighted >150 “molecules of the month” whose structures or stories were typically published for the first time. They were selected from thousands of research articles, published by leading institutions around the world. It was incredibly hard to narrow down the selection to just one molecule from each month, and it’s agonizing to leave so many amazing stories off this list, but here are 12 molecules from 2020 that our community would likely all agree we learned a lot from. The molecules were selected based on a range of factors, from clinical and commercial timeliness (such as Mirati’s market-moving KRAS inhibitor from April) to mechanistic proof of concept (such as GSK’s RIPK2 degrader with prolonged PD) to interesting modalities (such as Novartis’s reversible-covalent aldehyde FGFR4 inhibitor) to overcoming a brutal drug discovery campaign against a difficult mechanism of action (such as Gilead’s HIV capsid inhibitor).
Molecules of the Month
2020 Molecules of the Year Nominees
Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!
Join the Drug Hunter Mailing List
to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.
- 1.2023 Novel Small Molecule FDA Drug Approvals
- 2.Top 12 Most Popular Drug Hunter Case Studies of 2023
- 3.Top Ten Most Popular Drug Hunter Resources of 2023
- 4.Top 10 Most Popular Drug Hunter Review Articles of 2023
- 5.Practical PK Calculators
- 6.AACR Orlando 2023: New Drug Candidates
- 7.PK Cheat Sheet
- 8.Phase I Drug Metabolism
- 9.Why pKas Matter in Medicinal Chemistry and a Drug Discovery Amine pKa Table
- 10.Phase II Drug Metabolism
- 11.First Disclosures from ACS Chicago 2022
- 12.Topliss Tree and Topliss Scheme Posters
VIEW MORE CONTENT